46973 20200221144243.0 doi 10.1016/j.tube.2015.10.010 sideral 93398 ART-2016-93398 eng (orcid)0000-0001-7897-9173 Aguilo, N. Universidad de Zaragoza MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice 2016 Access copy available to the general public Unrestricted Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG. info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P info:eu-repo/grantAgreement/ES/MINECO/BIO2011-23555 This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020 info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020 info:eu-repo/grantAgreement/EC/FP7/241745/EU/Discovery and preclinical development of new generation tuberculosis vaccines/NEWTBVAC info:eu-repo/grantAgreement/ES/FECYT/INNOCASH-INC-098 info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 2.873 2016 MICROBIOLOGY 53 / 124 = 0.427 2016 Q2 T2 RESPIRATORY SYSTEM 23 / 59 = 0.39 2016 Q2 T2 IMMUNOLOGY 82 / 150 = 0.547 2016 Q3 T2 1.224 2016 Immunology 2016 Q2 Microbiology (medical) 2016 Q2 Microbiology 2016 Q2 Infectious Diseases 2016 Q2 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion (orcid)0000-0001-7866-2803 Uranga, S. Universidad de Zaragoza (orcid)0000-0001-8644-120X Marinova, D. Universidad de Zaragoza (orcid)0000-0002-2787-9671 Monzon, M. Universidad de Zaragoza (orcid)0000-0002-7173-7216 Badiola, J. Universidad de Zaragoza (orcid)0000-0003-2993-5478 Martin, C. Universidad de Zaragoza 1008 630 Universidad de Zaragoza Dpto. Microb.Med.Pr.,Sal.Públ. Área Microbiología 1003 443 Universidad de Zaragoza Dpto. Anatom.Histolog.Humanas Area Histología 1009 773 Universidad de Zaragoza Dpto. Patología Animal Área Sanidad Animal 1008 X Universidad de Zaragoza Dpto. Microb.Med.Pr.,Sal.Públ. Proy. investigación HQA 96 (2016), 71-74 TUBERCULOSIS TUBERCULOSIS 1472-9792 529840 http://zaguan.unizar.es/record/46973/files/texto_completo.pdf Versión publicada 109105 http://zaguan.unizar.es/record/46973/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:46973 articulos driver 2020-02-21-13:23:07 ARTICLE